APN-targeted NDS have been developed by various groups; for example, after the intravenous injection of the c-Myc siRNA loaded in NGR-modified PEGylated liposomes, they are delivered efficiently to the HT1080 fibrosarcoma cytoplasm. The gene discussed is MYC; the disease is fibrosarcoma.